What is William Blair’s Estimate for Medpace Q3 Earnings?

Medpace Holdings, Inc. (NASDAQ:MEDP) – Research analysts at William Blair cut their Q3 2025 earnings estimates for Medpace in a note issued to investors on Tuesday, February 11th. William Blair analyst M. Smock now expects that the company will post earnings per share of $2.99 for the quarter, down from their previous estimate of $3.18. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace’s Q4 2025 earnings at $2.93 EPS, FY2025 earnings at $12.12 EPS, Q1 2026 earnings at $3.38 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.50 EPS and Q4 2026 earnings at $3.57 EPS.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%.

Other research analysts also recently issued reports about the company. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $381.44.

Medpace Trading Up 2.6 %

Shares of Medpace stock opened at $336.47 on Thursday. The firm has a market cap of $10.46 billion, a PE ratio of 29.46, a PEG ratio of 1.85 and a beta of 1.36. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a 50 day moving average of $343.90 and a 200 day moving average of $348.96.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC grew its holdings in Medpace by 82.6% during the 3rd quarter. CWM LLC now owns 4,241 shares of the company’s stock valued at $1,416,000 after purchasing an additional 1,918 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Medpace by 47.7% in the third quarter. Exchange Traded Concepts LLC now owns 2,981 shares of the company’s stock worth $995,000 after purchasing an additional 963 shares during the last quarter. Swedbank AB purchased a new position in shares of Medpace during the third quarter valued at approximately $7,477,000. Vontobel Holding Ltd. grew its stake in shares of Medpace by 137.3% during the third quarter. Vontobel Holding Ltd. now owns 1,424 shares of the company’s stock valued at $475,000 after buying an additional 824 shares during the last quarter. Finally, Rheos Capital Works Inc. raised its holdings in shares of Medpace by 18.3% in the third quarter. Rheos Capital Works Inc. now owns 29,101 shares of the company’s stock worth $9,714,000 after buying an additional 4,500 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.